nosis and MDS evolution are currently known in AA. AA has genetic instability, and acquired somatic mutations of ASXL1, TET2, RUNX1, TP53, K-RAS and N-RAS typically occurred in MDS/AML. [7] [8] [9] [10] [11] We postulated that these mutations might be an early event in AA evolution to MDS/AML, and could predict MDS/AML evolution and prognosis. In this study, we analyzed mutations in ASXL1, TET2, RUNX1, TP53, K-RAS and N-RAS in Chinese AA patients and showed that somatic mutations that were common in myeloid malignancies also existed in AA. Moreover, patients with different mutations showed distinct clinical and biological features.
Bone to treatment (P=1.000) ( Table 1) . TET2 mutations were seen in 10 of 138 (7.3%) patients, and were closely associated with prior interventions. Mutations were detected in 5 of 19 (26.3%) patients who had received antithymocyte globulin (ATG)-based IST, compared with patients receiving cyclosporine (CsA)-based IST (1 of 42, 2.4%) and others (0 of 14, 0%); these differences were significant (P=0.008). TET2 mutations also were closely related with a good response. The frequency of TET2 mutations in patients with CR (6 of 36, 16.7%) was higher than those with PR (1 of 31, 3.2%) or NR (0%, 0 of 33); this difference was also significant (P=0.013). There was no significant difference between patients with or without TET2 mutations in terms of age (P=0.877), sex (P=0.155), severity of AA (P=0.234), or duration of disease (P=0.813) ( Table 2) . Of 138 patients, the PNH clone was negative in 118 patients, positive in 20 (14.5%); 10 were detected at diagnosis, and after diagnosis in the other 10. The metaphase cytogenetic karyotype was normal in 130 patients, trisomy 8 (n=3), del (13) (q12-q21) (n=2), monosomy 7 (n=1), 16qh+ (n=1) and complex karyotype (n=1) were detected in the remaining 8 patients (Online Supplementary Table S4 ). ASXL1 and TET2 mutations had no relationship with the PNH clone (P=0.672 and P=0.327, respectively) ( Tables 1  and 2 ). ASXL1 mutation were detected in 2 of 8 (25%) patients with abnormal cytogenetics, compared with patients with normal cytogenetics (12 of 130, 9.2%), but the difference was not significant (P=0.188) ( Table 1) , possibly because of the limited number of cases. Surprisingly, TET2 mutation had no relationship with abnormal cytogenetics (P=1.000), and was not detected in any patients with an abnormal cytogenetic profile (Table 2) .
Of the 100 AA patients who had complete clinical data available for analysis in evolution to MDS, progression to MDS was seen in 9 patients (Online Supplementary Table  S5 ). The median time of progression to MDS was 36.3 months (range 7-86 months), and in 6 of 9 patients occurred less than three years from diagnosis. Seven of 9 patients received CsA-based IST, the others ATG-based IST; 2 patients who evolved to MDS subsequently progressed to AML. The cytogenetic karyotype at the time of evolution was normal (n=5), monosomy 7 (n=1), trisomy 8 (n=1), del(13)(q12-q22) (n=1), and complex karyotype (n=1), respectively. The frequency of ASXL1 mutations was higher in patients who progressed to MDS than those who did not (3 of 9, 33.3% vs. 7 of 91, 7.7%; P=0.044) ( Table 1) . AA patients with ASXL1 mutations had a greater risk of transformation to MDS in univariate analysis (P=0.014) (Online Supplementary Figure S1A) . Surprisingly, TET2 mutations had no relationship with evolution to MDS in univariate analysis (P=0.464) (Online Supplementary Figure S1B) ; 1 of 9 (11.1%) patients with TET2 mutation evolved to MDS, compared to 7 of 91 (7.7%) patients without TET2 mutation, although this difference was not significant (P=0.543) ( Table 2) .
ASXL1 and TET2 mutations have been reported in various myeloid malignancies, 7-11 especially MDS/AML. Evolution of AA to MDS/AML is a serious and common long-term complication.
1-2,13 Little has been known about somatic mutations in AA until now. In this study, we found mutations in epigenetic regulator genes including TET2 and ASXL1 in 17.4% patients with AA. Mutations were detected at any stage of disease. The rate of mutation was similar to those reported in AA patients in the UK.
6 ASXL1 mutations were the most common mutation in AA, and were associated with a transformation to MDS. Meanwhile, ASXL1 mutations were relatively more frequently found in patients with abnormal cytogenetics compared with patients with normal cytogenetics. Kulasekararaj et al. 6 also found that 7 of 12 AA patients with ASXL1 mutations showed progression to MDS and were associated with 40% risk of transformation to MDS. In their report, ASXL1 mutation occurred more frequently in older patients, but we found ASXL1 mutation was more common in younger Chinese patients and those under nine years of age had the highest incidence. For the first time, TET2 mutations were found in AA. Surprisingly we found that AA patients with TET2 mutations had a better response to IST than those without mutations. The advantage resulted at least in part from the fact that TET2 mutations occurred more frequently in patients who had received ATG-based IST, and that TET2 mutations were not associated with abnormal cytogenetics and had no adverse effect on transformation to MDS. In addition, TET2 mutations were also associated with longer survival, lower risk of transformation to AML, and a molecular marker for good prognosis in patients with MDS.
14,15 TET2 mutations may have a good prognostic implication in AA, but this result needs to be further confirmed with larger series of patients.
In summary, we identified TET2 and ASXL1 mutations in Chinese patients with AA. These important data may predict disease outcomes in AA patients of diverse genetic backgrounds. 
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